BMP10 Protein Calms Aging Hearts and Lowers Atrial Fibrillation Risk in Aged Rats
Raising BMP10 in aged rats cut atrial fibrillation inducibility and scarring by restoring mitochondrial function in heart muscle cells via STAT3.
Résumé
Atrial fibrillation (AF), the most common sustained heart rhythm disorder, becomes far more likely with age, yet its biological roots in the aging heart remain unclear. Researchers in China found that blood levels of the protein BMP10 are higher in aged rats and in people with AF than in young controls. Surprisingly, boosting BMP10 further in aged rats using a gene therapy vector reduced how easily AF could be triggered, improved electrical conduction, and lowered atrial scarring and inflammation. The protein appeared to work by improving mitochondrial function in atrial muscle cells: it lowered damaging reactive oxygen species through STAT3 signaling and increased ATP-producing capacity. The findings are preclinical, but they suggest that mitochondrial health in the atria may be a promising target for age-related arrhythmia.
Résumé détaillé
Atrial fibrillation affects a growing share of older adults and raises the risk of stroke, heart failure, and death. Clinical studies have linked high circulating BMP10, a heart-enriched signaling protein, to worse outcomes in AF and in older people. Whether BMP10 drives the disease or is a bystander has been unknown.
This study tested the question directly. Aged rats received an adeno-associated virus 9 (AAV9) vector to overexpress BMP10, or a negative-control vector. After four weeks, the team assessed intracardiac electrophysiology, echocardiography, and tissue histology. They also ran proteomics on atrial tissue and examined mitochondrial structure, reactive oxygen species (ROS), and energy-related substrates.
Serum BMP10 was higher in aged rats and in AF patients than in young controls, and atrial BMP10 expression tracked with atrial remodeling and an AF-prone phenotype. Yet overexpressing BMP10 in aged rats reduced pacing-induced AF, increased conduction velocity, and decreased atrial fibrosis and inflammatory foci. Proteomics pointed to improved mitochondrial metabolism linked to STAT3 signaling. BMP10 lowered ROS by influencing phosphorylation and mitochondrial translocation of STAT3, and it boosted electron transport chain activity and ATP generation, with upregulated mitochondrial biogenesis markers.
The results suggest that the age-related rise in BMP10 may be a compensatory response rather than a cause, and that supporting atrial mitochondrial function could protect against arrhythmia. This fits a broader longevity theme: mitochondrial dysfunction and oxidative stress contribute to cardiac aging.
Important caveats apply. The work is largely in rats, uses viral overexpression that may exceed physiological levels, and followed animals for only four weeks. Human data appear limited to serum level comparisons. This summary draws only on the abstract, so sample sizes, sex of animals, and statistical details could not be evaluated.
Principales conclusions
- Serum BMP10 was higher in aged rats and AF patients than in young controls, and atrial BMP10 correlated with remodeling and AF phenotype.
- AAV9-mediated BMP10 overexpression in aged rats reduced pacing-induced AF incidence and increased atrial conduction velocity.
- BMP10 overexpression decreased atrial fibrosis and inflammatory foci while restoring electrical activity.
- BMP10 lowered mitochondrial ROS by regulating phosphorylated STAT3 translocation into mitochondria in atrial cardiomyocytes.
- BMP10 enhanced electron transport chain activity and ATP production, with upregulated mitochondrial biogenesis markers.
Méthodologie
Aged rats received AAV9-BMP10 or negative-control vector, followed by intracardiac electrophysiology with pacing, echocardiography, and histology at four weeks. Atrial proteomics, transmission electron microscopy, mitoSOX ROS staining, and metabolic assays probed mitochondrial mechanisms. Serum BMP10 was also compared between AF patients and controls and between young and aged rats.
Limites de l'étude
Findings come mainly from a rat model with viral overexpression over four weeks, so relevance to human atrial aging and long-term safety is unproven. The human component appears limited to serum level comparisons, and sample sizes, sex, and effect sizes were not available in the abstract. The abstract-only review also cannot confirm causality of the STAT3-mitochondria pathway or rule out off-target effects of BMP10 elsewhere.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :